Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Not listed Not applicable Interventional Accepts healthy volunteers

Migraine and Recurrent Abdominal Pain in Children

NCT00060619
Conditions
Migraine, Abdominal Pain
Interventions
thermal biofeedback, relaxation training, cognitive coping skills, parent education
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Results available

AMG 334 20160172 Pediatric Migraine PK Study.

NCT03499119
Conditions
Migraine
Interventions
AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Supraspinal Processing of Sensory Aspects of Pain

NCT05814497
Conditions
Migraine in Children, Complex Regional Pain Syndromes, Musculoskeletal Pain, Functional Abdominal Pain Syndrome, Fibromyalgia
Interventions
Multisensory Task, Graphesthesia, Divided attention
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
255 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Episodic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Conditions
Migraine in Children
Interventions
Valproic Acid (VPA), Dihydroergotamine (DHE)
Drug
Lead sponsor
Kimberly S Jones
Other
Eligibility
10 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Migraine Headaches
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Migraine Disorders, Photophobia
Interventions
Investigational Coating
Device
Lead sponsor
University of Utah
Other
Eligibility
7 Years to 18 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Migraine Disorders, Headache Disorders
Interventions
SPN-538, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Migraine
Interventions
Fremanezumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
32
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
Conditions
Migraine
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Newport Beach, California • Stamford, Connecticut + 5 more
Conditions
Headache Disorders, Migraine Disorders, Insomnia
Interventions
Intervention for Sleep and Pain in Youth
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Migraine
Interventions
Ketorolac, intranasal, Ketorolac, intravenous, Placebo, intravenous, Placebo, intranasal
Drug
Lead sponsor
Columbia University
Other
Eligibility
8 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Conditions
Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
6 Years to 12 Years
Enrollment
293 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more
Conditions
Migraine
Interventions
Eptinezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
New Haven, Connecticut • Stamford, Connecticut • Gulf Breeze, Florida + 17 more
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more
Conditions
Migraine
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
71
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 62 more
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Not listed Not applicable Interventional Accepts healthy volunteers

Intravenous Fluids in Pediatric Migraine

NCT06182098
Conditions
Migraine, Migraine in Children
Interventions
1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dayton, Ohio
Conditions
Insomnia, Migraine Disorders, Headache Disorders
Interventions
Internet-delivered CBT for Insomnia, Internet-delivered CBT for Pain Management, Internet-delivered Sleep Education
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 17 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 2 Interventional Results available

Treatment of Acute Migraine Headache in Children

NCT00355394
Conditions
Migrainous Headache
Interventions
Metoclopramide, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Migraine in Children, Migraine
Interventions
Eptinezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
6 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Stamford, Connecticut • Gulf Breeze, Florida • West Palm Beach, Florida + 6 more
Conditions
Acute Treatment of Migraine
Interventions
Zavegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hinesville, Georgia + 8 more